NCT05786443View on ClinicalTrials.gov

Safety and Efficacy of Empagliflozin in Hemodialysis

PHASE2RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2024

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2026

Conditions
End Stage Renal Disease
Interventions
DRUG

Empagliflozin 10 MG

Sodium glucose cotransporter 2 inhibitor (SGLT2i) dosed once-daily over 12 weeks. Administered as oral tablet.

DRUG

Placebo

Empagliflozin-matching placebo dosed once-daily over 12 weeks. Administered as oral tablet.

Trial Locations (2)

10016

RECRUITING

NYU Langone Health, New York

021215

RECRUITING

Brigham and Women's Hospital, Boston

Sponsors

Collaborators (1)

Boehringer Ingelheim
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

collaborator

Boehringer Ingelheim

INDUSTRY

lead

NYU Langone Health

OTHER

NCT05786443 - Safety and Efficacy of Empagliflozin in Hemodialysis | Biotech Hunter | Biotech Hunter